ClinicalTrials.gg
CompletedNCT01232127Updated Aug 31, 2012Results posted

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

A Phase 4 interventional study of Atazanavir and Atazanavir in HIV, sponsored by Bristol-Myers Squibb. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-31.

Sponsored by Bristol-Myers Squibb · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.

Read the detailed description

This protocol was designed to compare the pharmacokinetic parameters of atazanavir administered as atazanavir/ritonavir, 400/100 mg once daily (QD), plus famotidine, 20 mg and 40 mg twice daily, with the parameters found at the usual clinical dose of atazanavir/ritonavir, 300/100 mg QD, without famotidine in HIV-infected participants receiving tenofovir disoproxil fumarate and at least 1 other nucleoside reverse transcriptase inhibitor.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Males and females, 18 to 65 years of age, with infection and a of 18.0 to 35.0 kg/m\^2
  • HIV-infected participants receiving a treatment regimen containing only atazanavir/ritonavir, 300/100 mg once daily (QD) + tenofovir, 300 mg QD + at least 1 other nucleotide reverse transcriptase inhibitor continuously for at least 3 months prior to study day 1
  • Plasma HIV RNA levels of \<50 copies/mL and a >200 cells/mm\^3.
  • No history of virologic failure on a protease inhibitor (PI), documented phenotypic PI resistance, or primary PI mutations, according to International AIDS Society recommendations
  • No documented phenotypic resistance to atazanavir or primary genotypic mutations causing resistance to atazanavir
  • Women of who were not nursing or pregnant and were using an acceptable method of for at least 4 weeks before dosing, during the study, and for 8 weeks from the last dose of study drug.
  • Women with a negative pregnancy test result within 24 hours prior to dosing with study medication
  • Women not breastfeeding
  • Men willing or able to agree to practice barrier contraception for the duration of the study and at least 3 months after dosing.

Key exclusion criteria:

  • Any history of CD4 cell count \<50 cells/mm\^3
  • Previously documented phenotypic or genotypic resistance to any of the currently prescribed NRTIs
  • Any significant acute illness within 6 months of study day 1 or chronic medical illness unless stable or controlled by a nonprohibited medication
  • Any major surgery within 4 weeks of study day 1
  • Any gastrointestinal surgery that could impact upon the absorption of any study drug
  • Inability to be venipunctured and/or tolerate venous access
  • History of Gilbert's syndrome, hemophilia, chronic pancreatitis, hypochlorhydria, achlorhydria, gastroesophageal reflux disease, hiatal hernia, or peptic/gastric ulcer disease
  • Intractable diarrhea (≥ 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study day 1
  • Recent (within 6 months prior to study day 1) drug or alcohol abuse
  • Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, (ECG)
  • Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations, which would not be expected for the extent of HIV disease
  • Any of the following on 12-lead ECG prior to dosing on study day 1, confirmed by repeat: PR ≥ 210 msec; QRS ≥ 120 msec; ≥ 500 msec; QTcF ≥ 450 msec
  • Second- or third-degree A-V block or clinically relevant ECG abnormalities
  • Positive urine screen for drugs of abuse at screening or prior to dosing without a valid prescription. Positive urine drug screen for cannabinoids with or without a prescription is not exclusionary
  • , as estimated by method of Cockcroft and Gault, less than 60 mL/min
  • Liver enzyme levels > 3* the (ULN) prior to dosing on study day 1
  • Total level >10*ULN prior to study day 1
  • Positive blood screen for surface antigen or antibody.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Other
    Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI

    The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.

    Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)

  • Other
    Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)

    FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.

    Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI) · Drug: Famotidine (FAM)

  • Other
    Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)

    FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.

    Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir (TDF) · Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI) · Drug: Famotidine (FAM)

Interventions

  • Capsule, oral, 300 mg, once daily, 10 days

    Also known as: Reyataz, BMS-232632

  • Capsule, oral, 400 mg, once daily, 7 days

    Also known as: Reyataz, BMS-232632

  • Capsule, oral, 100 mg, once daily, 10 days

  • Capsule, oral, 100 mg, once daily, 7 days

  • Capsule, oral, 300 mg, once daily, 10 days

  • Capsule, oral, 300 mg, once daily, 7 days

  • DrugNucleoside Reverse Transcriptase Inhibitor (NRTI)

    Oral, 10 days

  • DrugNucleoside Reverse Transcriptase Inhibitor (NRTI)

    Oral, 7 days

  • DrugFamotidine (FAM)

    Tablet, oral, 20 mg, twice daily, 7 days

  • DrugFamotidine (FAM)

    Tablet, oral, 40 mg, twice daily, 7 days

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir

    Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

  2. Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir

    Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

  3. Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir

    Time frame: Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.

Secondary outcomes

  1. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.

  2. Number of Participants With Abnormalities in Vital Signs

    Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.

    Time frame: Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.

  3. Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings

    ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.

    Time frame: Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.

  4. Number of Participants With Abnormalities in Laboratory Test Results

    PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10\*3 c/uL): \<0.85\*PreRx, if PreRx \<1.5; \<1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): \>1.25\*PreRx if PreRx \>ULN; \>1.25\*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN. Bilirubin, total (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN.

    Time frame: Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.

07

Results

Posted Aug 28, 2012

Participant flow

Period 1: Days 1-10
Participant flow — Period 1: Days 1-10
MilestoneAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Started2500
Completed2400
Not completed100
Withdrew: Discontinued due to dosing error100
Period 2: Days 11-17
Participant flow — Period 2: Days 11-17
MilestoneAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Started0240
Completed0240
Not completed000
Period 3: Days 18-24
Participant flow — Period 3: Days 18-24
MilestoneAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Started0024
Completed0024
Not completed000

Outcome measures

SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest
ParticipantsAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Deaths000
SAEs000
AEs leading to discontinuation000
AEs675
AEs of clinical interest: Nausea020
AEs of clinical interest: Diarrhea030
SecondaryNumber of Participants With Abnormalities in Vital Signs

Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.

Time frame:
Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Number · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsAll Treated
Isolated decrease in heart rate2
Sporadic respiration rate >16 bpm11
PrimaryMaximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir
Time frame:
Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir
ng/mLAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Atazanavir Cmax3512 ± 35.44131 ± 37.73322 ± 45.2
Atazanavir Ctrough496 ± 50.9602 ± 60.3494 ± 59.4
Ritonavir Cmax1141 ± 30.51148 ± 29.81096 ± 36.1
Ritonavir Ctrough45.8 ± 58.749.2 ± 66.847.3 ± 53.4
PrimaryTime of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir
Time frame:
Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Median · Hours
Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir
HoursAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Atazanavir Tmax3.0 (2.0 to 4.0)3.0 (2.0 to 4.0)3.0 (2.0 to 4.10)
Ritonavir Tmax4.0 (2.0 to 4.2)4.00 (2.0 to 6.0)4.0 (2.0 to 6.0)
PrimaryArea Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir
Time frame:
Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir
ng*h/mLAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
Atazanavir AUC32562 ± 37.737894 ± 40.731481 ± 48.8
Ritonavir AUC7317 ± 35.67430 ± 32.47052 ± 36.7
SecondaryNumber of Participants With Abnormalities in Electrocardiogram (ECG) Findings

ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.

Time frame:
Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Number · Participants
Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings
ParticipantsAll Treated
Nonspecific ST/T wave abnormality1
Short PR interval1
SecondaryNumber of Participants With Abnormalities in Laboratory Test Results

PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10\*3 c/uL): \<0.85\*PreRx, if PreRx \<1.5; \<1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): \>1.25\*PreRx if PreRx \>ULN; \>1.25\*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN. Bilirubin, total (mg/dL), high: \>1.1\*ULN if PreRx ≤ULN;\> 1.1\*ULN if PreRx is missing; \>1.25\*PreRx if PreRx \>ULN.

Time frame:
Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.
Reported as:
Number · Participants
Number of Participants With Abnormalities in Laboratory Test Results
ParticipantsAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
WBC differential count (low)100
Neutrophils (absolute) (low)010
Alanine aminotransferase (high)010
Aspartate aminotransferase (high)001
Bilirubin, direct (high)100
Bilirubin, total (high)375

Adverse events

Collected over Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI—0/25 (0%)4/25 (16%)
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)—0/25 (0%)6/25 (24%)
Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)—0/24 (0%)1/24 (4.2%)
Most frequent other events
Most frequent other events
EventAtazanavir/Ritonavir (300/100) + TDF + ≥NRTIAtazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)
HeadacheNervous system disorders4/251/251/24
DiarrhoeaGastrointestinal disorders0/253/250/24
NauseaGastrointestinal disorders0/252/250/24

Baseline characteristics

Age, Customized
Age, Customized(Participants)All Treated
Younger than 65 years25
65 years and older0
Sex: Female, Male
Sex: Female, Male(Participants)All Treated
Female1
Male24
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Treated
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White20
More than one race0
Unknown or Not Reported0
Age
Age(Years)All Treated
Mean39.8 (23 to 62)
CD4 Absolute Count
CD4 Absolute Count(Cells/μL)All Treated
Mean584.8 ± 194.09
CD4 Percent of Total
CD4 Percent of Total(Percent of participants)All Treated
Mean32.1 ± 7.10
08

Study locations

2 sites
  • Local Institution
    Berlin, 14050, Germany
  • Local Institution
    London, Greater London SW10 9NH, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2010
First posted
Nov 2, 2010
Start
Feb 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Aug 28, 2012
Last update
Aug 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01232127
Responsible party
Sponsor
First posted
Nov 2, 2010
Start date
Feb 2011
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Aug 28, 2012
Last update
Aug 31, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atazanavir · Ritonavir · Tenofovir

Start the discussion